Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Quercetin in HSCT Survivors
NCT02652052Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Mar 2016
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of dasatinib and quercetin in frailty syndrome (2 arms), sponsored by Mayo Clinic. Primary endpoint: Frailty at 180 days. Started Mar 2016; status: completed.
02
Drugs
dasatinibquercetin
03
Conditions
frailty syndrome
Beyond the preview
Go deeper on NCT02652052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652052.